February 20, 2018 / 9:36 PM / 6 months ago

BRIEF-Spring Bank Pharmaceuticals Reports Q4 Loss Per Share $0.11

Feb 20 (Reuters) - Spring Bank Pharmaceuticals Inc:

* SPRING BANK PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL AND OPERATIONAL RESULTS

* Q4 LOSS PER SHARE $0.11

* SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE REQUIREMENTS INTO Q4 2019

* SPRING BANK PHARMA - EXPECTS CASH, CASH EQUIVALENTS AS OF DEC 31, 2017 WILL NOT BE SUFFICIENT TO FUND INITIATION OF ANY PHASE 3 TRIAL FOR INARIGIVIR

* SPRING BANK PHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $50.6 MILLION AS OF DEC 31, 2017, COMPARED TO $25.5 MILLION AS OF DEC 31, 2016 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below